1. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
   Taeyun Kim et al, 2023, Cancer Research and Treatment CrossRef
2. Clinical phase II trial shows that combining osimertinib and afatinib resistance EGFR recurrent mutation in EGFR-mutant lung cancer
   Tshetiz Dahal et al, 2024, Southeast Asian Journal of Health Professional CrossRef
3. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
   null Santoni-Rugiu et al, 2019, Cancers CrossRef
4. Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis
   Z.-X. Li et al, 2020, Clinical and Translational Oncology CrossRef